258 related articles for article (PubMed ID: 38392072)
1. Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology.
Batra A; Glick D; Valdes M
Curr Oncol; 2024 Feb; 31(2):1047-1062. PubMed ID: 38392072
[TBL] [Abstract][Full Text] [Related]
2. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Management of Metastatic Prostate Cancer.
Sayegh N; Swami U; Agarwal N
JCO Oncol Pract; 2022 Jan; 18(1):45-55. PubMed ID: 34473525
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
7. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
8. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
[TBL] [Abstract][Full Text] [Related]
10. Novel breakthroughs in advanced prostate cancer management.
Lilly E; Sarkis J; Mahmoud O; El Gharib K; Sarkis P; Nemr E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):369-373. PubMed ID: 36951118
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
[TBL] [Abstract][Full Text] [Related]
12. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors.
Maiorano BA; Conteduca V; Catalano M; Antonuzzo L; Maiello E; De Giorgi U; Roviello G
Crit Rev Oncol Hematol; 2023 Dec; 192():104157. PubMed ID: 37863403
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
16. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
17. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
18. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
[TBL] [Abstract][Full Text] [Related]
19. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
20. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
